Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Fan, S T ^a   Cheung, S T ^a   Lo, C M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; OIL; OKT 3; VIRUS DNA; VIRUS RNA;

ARTIFICIAL EMBOLISM; CANCER INVASION; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; GRAFT REJECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION PREVENTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 0033946748     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02119.x     Document Type: Conference Paper

References (64)

1. Samuel D, Bismuth A, Mathieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991; 337: 813-15.
2. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-26.
3. Jurim O, Martin P, Shaked A et al. Liver transplantation for chronic hepatitis in Asians. Transplantation 1994; 57: 1393-5.
4. Ho BM, So SK, Esquivel CO, Keeffe EB. Liver transplantation in Asian patients with chronic hepatitis B. Hepatology 1997; 25: 223-5.
5. Samuel D, Muller R, Alexander G et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 1993; 329: 1842-7.
6. Terrault NA, Zhou S, Combs C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-33.
7. Nymann T, Shokouh-Amiri MH, Vera SR, Riely CA, Alloway RR, Gaber AO. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin. Transplant. 1996; 10: 663-7.
8. Lerut JP, Donataccio M, Ciccarelli O et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: Adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J. Hepatol. 1999; 30: 706-14.
9. McGory RW, Ishitani MB, Oliveira WM et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358-64.
10. Sawyer RG, McGory RW, Gaffey MJ et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann. Surg. 1998; 227: 841-50.
11. Lowell JA, Burgess S, Shenoy S, Peters M, Howard TK. Mercury poisoning associated with hepatitis-B immunoglobulin. Lancet 1996; 347: 480.
12. Shields PL, Owsianka A, Carman WF et al. Selection of hepatitis B surface 'escape' mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function. Gut 1999; 45: 306-9.
13. Rodriguez-Frias F, Buti M, Jardi R et al. Genetic alterations in the S gene of hepatitis B virus in patients with acute hepatitis B, chronic hepatitis B and hepatitis B liver cirrhosis before and after liver transplantation. Liver 1999; 19: 177-82.
14. Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
15. Nery JR, Weppler D, Rodriguez M, Ruiz P, Schiff ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B recurrence after liver transplantation. Transplantation 1998; 65: 1615-21.
16. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349: 20-2.
17. Ben Ari Z, Zemel R, Kazetsker A, Fraser G, Tur-Kaspa R. Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Am. J. Gastroenterol. 1999; 94: 663-7.
18. Allen MI, Deslauriers M, Andrews CW et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigaton Group. Hepatology 1998; 27: 1670-7.
19. Lai CL, Ching CK, Tung AK et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial. Hepatology 1997; 25: 241-4.
20. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
21. Ono-Nita SK, Kato N, Shiratori Y et al. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999; 29: 939-45.
22. Ben Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 232-6.
23. Mutimer D, Pillay D, Dragon E et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol. 1999; 30: 715-21.
24. Lo CM, Fan ST, Lai CL et al. Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. Transplant. Proc. 1999; 31: 535-6.
25. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutation in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-73.
26. Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
27. Dickson RC, Wright RM, Bacchetta MD et al Quality of life of hepatitis B and C patients after liver transplantation. Clin. Transplant. 1997; 11: 282-5.
28. Boker KH, Dalley G, Bahr MJ et al. Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 1997; 25: 203-10.
29. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 1996; 334: 815-20.
30. Ghobrial RM, Farmer DG, Baquerizo A et al. Orthotopic liver transplantation for hepatitis C. Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann. Surg. 1999; 229: 824-31.
31. Singh N, Gayowski T, Wagener MM, Marino IR. Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 1999; 67: 69-72.
32. Bona MD, Rupolo G, Ponton P et al. The effect of recurrence of HCV infection of life after liver transplantation. Transplant Int. 1998; 11: S475-9.
33. Chazouilleres O, Kim M, Combs C et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994; 106: 994-9.
34. Duvoux C, Pawlotsky JM, Cherqui D et al. Serial quantitative determination of hepatitis C virus RNA levels after liver transplantation: A useful test for diagnosis of hepatitis C virus reinfection. Transplantation 1995; 60: 457-61.
35. Feray C, Gigou M, Samuel D et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 1137-43.
36. Gane EJ, Naoumov NV, Qian KP et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167-77.
37. Villa E, Grottola VE, Buttafoco P et al. Long-term follow-up of hepatitis C virus (HCV) infection in liver transplant patients. Clin. Transplant. 1995; 9: 160-4.
38. Singh N, Gayowski T, Ndimbie OK, Nedjar S, Wagener MM, Yu VL. Recurrent hepatitis C viral hepatitis in liver transplant recipients receiving tacrolimus: Association with rejection and increased immunosuppression after transplantation. Surgery 1996; 119: 452-6.
39. Sheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30-4.
40. Rosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am. J. Gastroenterol. 1997; 92: 1453-7.
41. Papatheodoridis GV, Barton SG, Andrew D et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999; 45: 427-34.
42. Tisone G, Angelico M, Palmieri G et al. A pilot study on the safety and effectiveness of immunosuppression without prednisone after liver transplantation. Transplantation 1999; 67: 1308-13.
43. Dodson SF, Issa S, Bonham A. Liver transplantation for chronic viral hepatitis. Surg. Clin. North Am. 1999; 79: 131-45.
44. Prieto M, Berenguer M, Rayon JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250-6.
45. Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30.
46. Casino C, Lilli D, Rivanera D et al. Recurrence of hepatitis C virus infection after orthotopic liver transplantation: Role of genotypes. New Microbiol. 1999; 22: 11-18.
47. Vargas HE, Laskus T, Wang LF et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transplant. Surg. 1998; 4: 22-7.
48. Feray C, Samuel D, Gigou M et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology 1995; 22: 1084-9.
49. Wright TL, Combs C, Kim M et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20: 773-9.
50. Gane EJ, Lo SK, Riordan SM et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-7.
51. Bizollon T, Palazzo U, Ducerf C et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26: 500-4.
52. Sheiner PA, Boros P, Klion FM et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-8.
53. Singh N, Gayowski T, Wannstedt CF et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998; 65: 82-6.
54. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: A registry report of the impact of tumor characteristics on outcome. Ann. Surg. 1998; 228: 479-90.
55. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N. Engl. J. Med. 1996; 334: 693-9.
56. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann. Surg. 1993; 218: 145-51.
57. Otto G, Heuschen U, Hofmannn WJ, Krumm G, Hinz U, Herfarth C. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: A retrospective analysis. Ann. Surg. 1998; 227: 424-32.
58. Min AD, Saxena R, Thung SN. et al. Outcome of hepatitis C patients with and without hepatocellular carcinoma undergoing liver transplant. Am. J. Gastroenterol. 1998; 93: 2148-53.
59. Figueras J, Jaurrieta E, Valls C et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 1997; 25: 1485-9.
60. Harnois DM, Steers J, Andrews JC et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transplant. Surg. 1999; 5: 192-9.
61. Veltri A, Grosso M, Martina MC et al. Effect of preoperative radiological treatment of hepatocellular carcinoma before liver transplantation: A retrospective study. Cardiovasc. Intervent. Radiol. 1998; 21: 393-8.
62. Lo CM, Fan ST, Liu CL et al. Adult-to-adult living donor liver transplantation using extended right lobe graft. Ann. Surg. 1997; 226: 261-70.
63. Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology 1998; 28: 436-42.
64. Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: A systematic review. Liver Transplant. Surg. 1999; 5: 91-5.